Birt-Hogg-Dubé syndrome ͉ kidney cancer ͉ mouse model ͉ mTOR ͉ tumor suppressor B irt-Hogg-Dubé (BHD) syndrome is an inherited kidney cancer syndrome which predisposes patients to develop hair follicle tumors, lung cysts, spontaneous pneumothorax, and an increased risk of renal neoplasia (1-3). We previously identified germline mutations in the BHD (FLCN) gene in patients with BHD (4). About one-third of BHD patients develop bilateral multifocal renal tumors that are most frequently chromophobe renal tumors and renal oncocytic hybrid tumors with features of chromophobe renal carcinoma and renal oncocytoma (5). Somatic mutations in the wild-type copy of BHD and loss of heterozygosity at chromosome 17p11.2 have been identified in human BHD tumors, indicating that BHD is a classical tumor suppressor gene (6). The BHD protein folliculin (FLCN) is a 64-kDa protein with no known functional domains (4). We reported two FLCN binding proteins FNIP1 and FNIP2, which interact with 5Ј-AMP-activated protein kinase (AMPK), an important energy sensor in cells that negatively regulates mammalian target of rapamycin (mTOR), the master switch for cell growth and proliferation (7-9). These findings suggest that FLCN may play a role in cellular energy and nutrient sensing through interactions with the AMPK-mTOR signaling pathway. Mutations in several other tumor suppressor genes, including LKB1 (10), PTEN (11), and TSC1/2 (12), have been shown to lead to dysregulation of PI3K-AKT-mTOR signaling and to the development of other hamartoma syndromes. We and others previously reported the generation of a conditionally targeted BHD allele and kidney-directed BHD inactivation in the mouse using the cadherin16 (KSP)-Cre transgene (13, 14) . Although BHD homozygous deletion in kidney epithelial cells was sufficient to cause uncontrolled cell proliferation and hyperplastic cell transformation, the kidney-targeted BHD-knockout mice lived only approximately 3 weeks and did not produce kidney tumors. A BHD heterozygous knockout mouse model that develops tumors with age will more accurately reflect tumor development in the human BHD patient and may be a better model for understanding how BHD inactivation leads to tumor initiation and progression. Here we report the analysis of an embryonic lethal phenotype that occurs in a BHD homozygous knockout mouse model and characterize and compare the kidney tumors that develop in a BHD heterozygous knockout mouse model with human BHD kidney tumors.
B
irt-Hogg-Dubé (BHD) syndrome is an inherited kidney cancer syndrome which predisposes patients to develop hair follicle tumors, lung cysts, spontaneous pneumothorax, and an increased risk of renal neoplasia (1) (2) (3) . We previously identified germline mutations in the BHD (FLCN) gene in patients with BHD (4) . About one-third of BHD patients develop bilateral multifocal renal tumors that are most frequently chromophobe renal tumors and renal oncocytic hybrid tumors with features of chromophobe renal carcinoma and renal oncocytoma (5) . Somatic mutations in the wild-type copy of BHD and loss of heterozygosity at chromosome 17p11.2 have been identified in human BHD tumors, indicating that BHD is a classical tumor suppressor gene (6) . The BHD protein folliculin (FLCN) is a 64-kDa protein with no known functional domains (4) . We reported two FLCN binding proteins FNIP1 and FNIP2, which interact with 5Ј-AMP-activated protein kinase (AMPK), an important energy sensor in cells that negatively regulates mammalian target of rapamycin (mTOR), the master switch for cell growth and proliferation (7) (8) (9) . These findings suggest that FLCN may play a role in cellular energy and nutrient sensing through interactions with the AMPK-mTOR signaling pathway. Mutations in several other tumor suppressor genes, including LKB1 (10), PTEN (11) , and TSC1/2 (12) , have been shown to lead to dysregulation of PI3K-AKT-mTOR signaling and to the development of other hamartoma syndromes. We and others previously reported the generation of a conditionally targeted BHD allele and kidney-directed BHD inactivation in the mouse using the cadherin16 (KSP)-Cre transgene (13, 14) . Although BHD homozygous deletion in kidney epithelial cells was sufficient to cause uncontrolled cell proliferation and hyperplastic cell transformation, the kidney-targeted BHD-knockout mice lived only approximately 3 weeks and did not produce kidney tumors. A BHD heterozygous knockout mouse model that develops tumors with age will more accurately reflect tumor development in the human BHD patient and may be a better model for understanding how BHD inactivation leads to tumor initiation and progression. Here we report the analysis of an embryonic lethal phenotype that occurs in a BHD homozygous knockout mouse model and characterize and compare the kidney tumors that develop in a BHD heterozygous knockout mouse model with human BHD kidney tumors.
Results
Role of BHD during Early Embryogenesis. We have analyzed mouse BHD mRNA expression levels by qRT-PCR in wild-type embryos and adult tissues (Fig. S1 ). We detected consistent BHD mRNA expression from E8.5 to E12.5 with 4-fold elevation at E19 and high expression in adult heart, pancreas, and prostate with moderate expression in adult brain, kidney, liver, and lung. BHD mRNA expression was further analyzed during early embryogenesis by whole mount in situ hybridization (Fig. S2) . BHD mRNA was expressed consistently throughout embryogenesis. At E5.5, BHD expression was restricted to extraembryonic tissues; however, by E6.5, BHD was expressed in both embryonic and extraembryonic tissues. We saw strong expression in certain tissues including neural ectoderm, headfold, and limb buds, but the signal was relatively weak in the surrounding endoderm and heart.
Next we evaluated BHD homozygous knockout (BHD (Fig. 1H) . Immunohistochemical staining with the visceral endoderm (VE) marker DAB2 confirmed that the outer cell layer was VE ( Fig. 1 J-M) . Interestingly, VE of the BHD d/d embryos showed distorted enlarged cytoplasm and a disorganized structure ( Fig. 1 K and  M) instead of a cuboidal epithelial layer as seen in the BHD d/ϩ embryos ( Fig. 1 J and L) . Also the nuclei of the VE cells were disorientated in BHD d/d embryos (Fig. 1H') , whereas nuclei were aligned along the basal membrane in an orderly fashion in BHD ϩ/ϩ embryos (Fig. 1F') (Fig. 2 A and B) . Two of 23 BHD ϩ/ϩ mice displayed small, isolated simple cysts in their kidneys. The median age of kidney-lesion-free survival for BHD d/ϩ mice was 23 months (n ϭ 65), compared with an undefined kidney-lesion-free survival for BHD ϩ/ϩ littermate controls (n ϭ 28, P Ͻ 0.0001) (Fig. 2C) . No solid kidney tumors developed in BHD ϩ/ϩ mice (BHD d/ϩ median tumor-free survival ϭ 25 months, n ϭ 65; BHD ϩ/ϩ median tumor-free survival ϭ undefined, n ϭ 28; P ϭ 0.0026) (Fig. 2D) . The number of kidney lesions in BHD d/ϩ mice between the ages of 20 and 25 months is shown in Fig. 2E (n ϭ 35; no. cysts per animal, mean ϭ 3.43, SD ϭ 3.13; no. mixed lesions per animal, mean ϭ 0.51, SD ϭ 0.85; no. solid tumors per animal, mean ϭ 0.51, SD ϭ 0.82). Histological examination showed that kidney cysts that develop in BHD d/ϩ mice were lined by hyperplastic cells with enlarged cytoplasm and nuclei (Fig. 3A) with some structure or solid portions in the lumen, were observed. These complex cysts showed papillary protrusions into the lumen (Fig. 3B ) as well as regions containing solid tumor (Fig. 3C ). Interestingly the solid tumors displayed histologies similar to human kidney tumors that develop in BHD patients, including clear cell (Fig. 3D) , oncocytic hybrid consisting of a mixture of chromophobe renal carcinoma and oncocytic cells (Fig. 3E) , and oncocytoma (Fig. 3F) . Southern blot analysis of tumors that formed in BHD d/ϩ mice showed a severely reduced wild-type BHD allele signal compared to adjacent normal kidney tissue, supporting LOH at the BHD locus (Fig. 3G) . Western blot analysis showed only very weak FLCN expression in the tumors compared with adjacent BHD d/ϩ kidney or wild-type kidney tissue (Fig. 3H) , thus confirming the inactivation of both BHD alleles. Loss of endogenous FLCN expression was also confirmed by immunofluorescent staining using the Duolink in situ proximity ligation assay (PLA), which enables visualization of endogenous FLCN with two different antibodies ( Fig. 3 I and J) . Importantly all five kidney tumors that were analyzed from BHD d/ϩ mice showed very low FLCN expression compared to normal mouse kidneys. These results strongly support the premise that kidney tumors, which developed in the BHD d/ϩ mouse model, were produced as a consequence of loss of FLCN function.
Activation of the PI3K-AKT-mTOR Signaling Pathway in Kidney Tumors
from BHD d/؉ Mice and Human BHD Patients. Total AKT protein levels, AKT1, and AKT2 as well as total AKT, were dramatically elevated in kidney tumors compared with normal kidney tissue (Fig. 4A) . Levels of AKT phosphorylation were also dramatically elevated at both the PDK1 phosphorylation site (Thr308) and the mTORC2 phosphorylation site (Ser473) (15) (Fig. 4 A and  B) . AKT mRNA levels were measured by qRT-PCR in the same samples (Fig. 4C) . Contrary to the Western blot results, mRNA levels of AKT1 and AKT2 were not significantly different between tumors and normal kidneys. Increased phosphorylation of downstream effectors of AKT signaling would support AKT activation in kidney tumors that developed in BHD d/ϩ mice. Indeed, p-GSK3, p-FOXO1, and p-FOXO3a were elevated in tumors compared with normal kidneys (Fig. 4 D-F) . We also saw Cyclin D1 elevation, which might be a consequence of GSK3 phosphorylation (Fig. 4D) . mTOR phosphorylation on serine 2448, which reflects mTORC1 activation (16), was higher in tumors than in normal kidneys. Furthermore, mTOR phosphorylation on serine 2481, indicating mTORC2 activation (17) , was also higher in tumors compared with normal kidney tissue (Fig.  5A ). Interestingly Rictor was more highly expressed in tumors from BHD d/ϩ mice, which may lead to mTORC2 activation and result in higher AKT phosphorylation on serine 473. Levels of phospho(p)-S6 kinase (Thr421/Ser424) and phospho S6 ribosomal protein (Ser240/244), readouts of mTORC1 activation, were higher in tumors than in normal kidney tissue, although total protein levels of S6K and S6R were also elevated (Fig. 5A) . Consistent with the Western blot results, we were able to see stronger p-mTOR (Ser2448) and p-S6R (Ser240/244) staining in cells lining the cysts and in tumors from BHD d/ϩ mice when compared to adjacent normal kidney (Fig. 5 B-G) .
Finally we evaluated these protein levels in human BHD tumors and normal kidneys. Western blotting and immunofluorescent staining showed higher levels of p-AKT(Ser473) in kidney tumors compared to normal kidney controls (Fig. 6 A, E, and F). We quantified p-AKT(Ser473), p-S6K(Thr421/Ser424), and p-S6R(Ser240/244) using a Meso Scale Discovery multiplex microtiter plate assay, a quantitative assay system using a combination of electrochemiluminescence detection and patterned arrays (Fig. 6 B-D) . The protein levels of p-AKT (Ser473) were more than 30 times higher in human BHD tumors than in normal kidneys. Levels of p-S6K (Thr421/Ser424) protein and p-S6R protein were also higher in the BHD kidney tumors (Fig.  6 C and D) . We compared the genotype and phenotype of the BHD patients whose kidney tumors were evaluated in this study (Fig. 6G) . The kidney tumors were surgical specimens from three different female patients with different types of germline BHD mutations: missense, splicing defect and frameshift. All of the patients with different BHD mutations showed the classic triad of BHD phenotypic features-fibrofolliculomas, pulmonary cysts and renal tumors (Fig. S3) . Importantly, the molecular phenotype was similar among the tumors derived from these three different types of BHD alterations, underscoring the importance of PI3K-AKT-mTOR activation for kidney tumorigenesis in BHD patients.
Discussion
The early embryonic lethality of BHD homozygous knockout mice supports an essential role for BHD in mouse development. to nutrient uptake and transport, the anterior VE plays an active role in formation of the proamniotic cavity during the postimplantation period (18) . Although other naturally-occurring animal models for BHD have been described (20, 21) , they may harbor additional genetic changes that could confound studies of the functional consequences of BHD inactivation. The genetically engineered mouse model in this report provides a ''clean'' system with which to pursue FLCN functional studies. Hartman et al. (22) BHD or by another molecular mechanism. If the FLCN-␤geo fusion protein has partial function it could down-regulate mTOR and explain the discrepancy between the mTOR activation seen in tumors that developed in our BHD d/ϩ mice and the reduced mTOR activity reported by Hartman in tumors that developed in the gene trap mouse model for BHD. One additional difference between the two studies was the method of tissue preservation for immunostaining, which may affect the antigenicity of certain proteins. In this report freshly frozen tissues in OCT compound were analyzed, whereas paraffin embedded tissues were used in the Hartman's study. We found PI3K-AKT-mTOR pathway activation in both kidney tumors from BHD d/ϩ mice and human BHD tumors, consistent with the kidney-targeted BHD knockout kidney results, supporting a role for PI3K-AKT-mTOR pathway in both BHD null kidney tumorigenesis and in the development of hyperplastic kidney cysts. Interestingly, total AKT protein levels were elevated in those tumors without changes in AKT mRNA levels. Therefore FLCN may be involved in regulation of total AKT protein levels through post-translational or post transcriptional modification. It is possible that elevated total AKT could result in higher AKT activation as indicated by elevated AKT phosphorylation (Thr308/Ser473). AKT downstream target molecules were also highly phosphorylated in tumors from BHD d/ϩ mice, supporting the possibility that elevated total AKT may be driving the activation of the AKT pathway. Downstream of AKT, we found mTORC1 was activated in tumors from BHD d/ϩ mice. The high levels of p-AKT (Ser473) suggest mTORC2 activation. As expected, we saw elevated levels of pmTOR on Ser2481, a readout of mTORC2 activity (17) , in the mouse kidney tumors. Additionally we observed elevated Rictor expression in tumors from BHD d/ϩ mice. mTORC2 activity is regulated by Rictor expression level (23) , and Facchinetti et al. reported that mTORC2 phosphorylated AKT on the turn motif and stabilized AKT (24) . Taken together, the high expression level of Rictor and subsequent activation of mTORC2 may be the primary mechanism by which AKT activation occurs in BHD null tumors. Previously we found that FLCN phosphorylation was partially blocked by rapamycin (7) , suggesting that FLCN function may be regulated by mTOR. This may support a hypothesis whereby FLCN is on a negative feedback loop suppressing PI3K-AKT-mTOR signaling (Fig. S4) .
Each kidney tumor from human BHD patients that was analyzed showed PI3K-AKT-mTOR activation, regardless of type of BHD mutation. Most frameshift or splicing defect mutations found in BHD patients are predicted to produce aberrant mRNAs that would be degraded by nonsense mediated decay. Two different missense mutations have been reported to date; however, the physiological significance of these mutations has yet to be determined. Tumor 1 with the H255Y missense mutation (Fig. 6 A and G) showed the same molecular phenotype as the tumors from patients with germline frameshift or splicing mutations, suggesting loss of function of this mutant FLCN protein. Our data are consistent with a common consequence of BHD inactivation in mouse and man, regardless of BHD mutation type, and support activation of AKT signaling as an important mechanism driving kidney tumorigenesis in BHD syndrome. Rapamycin does not inhibit mTORC2 effectively, which may explain its partial effect on kidney-targeted BHD knockout mice (13) . Taken together, data generated from our two BHD mouse models suggest that mTORC2 as well as mTORC1 inhibition may be needed for the development of an effective form of therapy for patients with BHD-associated kidney cancer.
Materials and Methods
Development of BHD Knockout Mouse Model. The BHD heterozygous knockout mice were generated as previously described (13) . Details of the targeting strategy are described in the SI Methods (Fig. S5) . All mice which were used in these experiments were housed in the National Cancer Institute (NCI)-Frederick animal facility according to the NCI-Frederick Animal Care and Use Committee guidelines.
PCR-Based BHD Genotyping. Mouse genomic DNA was isolated from tails (weaned neonates), yolk sacs (E8.5 or later), and whole embryos (E7.5 or earlier). Primers and details are in the SI Methods.
Quantitative Real Time-PCR. The qRT-PCR for BHD, AKT1, and AKT2 was performed as described in the SI Methods. 
